Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

BTX / BioTime, Inc. BIOTIME, INC. 8-K (Current Report)

2018-02-22 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 21, 2018 BioTime, Inc. (Exact name of registrant as specified in its charter) California 1-12830 94-3127919 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. (7-0)

BioTime May Very Well Be The Wayne Gretzky Of Clinical Stage Biotech Companies

2018-02-21 seekingalpha
BioTime (BTX) may very well be the Wayne Gretzky of clinical stage biotech companies with countless shots on goal. The mini-conglomerate of stem cell technology has a massive array of market opportunities, in part because of the enormous portfolio of assets acquired from Geron (GERN) in 2013. Not only do I feel BioTime's core business is undervalued by the market, but likewise, its significant investments in publicly traded spin-offs Asterias Biotherapeutics (AST) and OncoCyte (OCX) are also each seemingly underappreciated by the market. (14-0)

BRIEF-BioTime Says Funds Raised Last Year To Fund Operations Well Into 2019​

2018-01-22 reuters
* BIOTIME INC - ‍ FUNDS RAISED TOWARDS END OF LAST YEAR PROVIDE CO SUFFICIENT CAPITAL, AT CURRENTLY PLANNED SPENDING LEVELS, TO FUND OPERATIONS WELL INTO 2019​ Source text for Eikon: Further company coverage: (9-1)

Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results

2018-01-03 seekingalpha
Today we will discuss the latest update from Achaogen (AKAO). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market. According to Blake Wise, Achaogen’s CEO, the number of confirmed cases of CRE annually in the U.S. alone total at least 70,000. More important, Wise noted is that the number is projected to double by 2022. (224-6)

Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys

2017-12-20 zacks
Chicago, IL – Dec 20, 2017 - Stocks in this week’s article include: BioTime Inc. (BTX - Free Report) , Ritter Pharmaceuticals Inc. (RTTR - Free Report) , Organovo Holdings Inc. (ONVO - Free Report) , American Superconductor Corp. (AMSC - Free Report) and Stratasys Ltd. (SSYS - Free Report) . (116-2)

BTX / BioTime, Inc. RDER

2017-12-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION December 14, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 BioTime, Inc. File No. 001-12830 - CF#35726 _____________________________ BioTime, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 9, 2017.

BTX / BioTime, Inc. (Current Report)

2017-12-11 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (date of earliest event reported): December 5, 2017   BioTime, Inc. (Exact name of registrant as specified in its charter)   California   1-12830   94-3127919 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.

Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys

2017-12-05 zacks
Chicago, IL – Dec 5, 2017 - Stocks in this week’s article include: BioTime Inc. (BTX - Free Report) , Ritter Pharmaceuticals Inc. (RTTR - Free Report) , Organovo Holdings Inc. (ONVO - Free Report) , Signal Genetics Inc. (MGEN - Free Report) and Stratasys Ltd. (SSYS - Free Report) . (200-3)

Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks

2017-12-04 zacks
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The general perception is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run is behind investors’ inclination toward low P/E stocks. (121-0)

Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime

2017-12-01 zacks
Chicago, IL – December 1, 2017 - Stocks in this week’s article Akari Therapeutics, Plc (AKTX - Free Report) , The Joint Corp. (JYNT - Free Report) , Tailored Brands, Inc. (TLRD - Free Report) ,  Ardelyx, Inc. (ARDX - Free Report) and BioTime, Inc. (BTX - Free Report) . (84-1)

5 Affordable Breakout Stocks Offering Excellent Returns

2017-11-30 zacks
Investors with an active approach often utilize a breakout investment strategy in their quest for appreciably high returns. This involves zeroing in on stocks trading within a tight band and buying them when they move out of this band. In keeping with this approach, such stocks are sold whenever they move below this narrow band. If properly implemented, such a strategy has the ability to deliver impressive returns. (52-0)

BTX / BioTime, Inc. ER

2017-11-10 sec.gov
June 22, 2017 Michael West Co-Chief Executive Officer BioTime, Inc. 1010 Atlantic Avenue, Suite 102 Alameda, CA 94501 BioTime, Inc. Registration Statement on Form S-3 Filed June 16, 2017 File No. 333-218807 Re: Dear Dr. West: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration.

BTX / BioTime, Inc. ESP

2017-11-10 sec.gov
BioTime, Inc. 1010 Atlantic Avenue, Suite 102 Alameda, California 94501 June 26, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn:    Dorrie Yale Re: BioTime, Inc.   Registration Statement on Form S-3   File No. 333-218807   Request for Acceleration Acceleration Request Request Date: June 28, 2017 Request Time: 9:30 a.


CUSIP: 09066L105